Drug-coated balloon (DCB) angioplasty has become a valuable alternative to drug-eluting stents in treating coronary artery disease. To achieve optimal outcomes, proper lesion preparation and techniques to minimise drug loss are crucial.

This article highlights key steps and best practices for performing DCB angioplasty, ensuring effective drug delivery and...

Impella CP microaxial flow pump supports complete revascularisation during high-risk PCI, but standard implantation often leads to vascular complications. This article explores an initial experience with a sheathless implantation technique, which shows promise as a feasible and safe alternative.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Pierre Deharo and Giuseppe Di Gioia provide their take on this analysis of the 5 years incidence, outcomes and predictors of hemodynamic SVD in patients undergoing TAVI and surgery from the Corevalve US Pivotal and SURTAVI trials.

Paris, France. 21 May 2021.  Since 1989, EuroPCR has constantly pioneered innovative educational tools and formats to help the interventional cardiovascular community effectively share their knowledge, skills and practice. Rising up to the challenge of the pandemic, the 31st annual edition was fundamentally rethought, reshaped and...

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Nicola Ryan provides her take on this clinical trial presented by Lisa Mielniczuk at the American College of Cardiology Scientific Session (ACC.23/WCC) – note this analysis is based upon the presented slides alone.

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Alex Sticchi provides his take on the 5-year outcomes from PARTNER 3 Low Risk which were presented by Martin B. Leon at TCT Congress 2023.

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.

What’s the safest approach when surgical options are off the table? This real-life case shows how complex coronary revascularsation and TAVI were performed in a single session, supported by Impella.

Explore the rationale behind the sequence, the device choices, and the outcome in a high-risk patient with...

Mirvat Alasnag provides her take on REC-CAGEFREE I, a multicenter, non-inferiority trial presented at the ESC Congress 2024 in London.

Aaysha Cader and Ali Nazmi Calik provide their take on the BHF PROTECT-TAVI trial, presented by Rajesh Kharbanda at ACC.25 in Chicago.

The data from this study suggest that, from a SoMe perspective, correct Impella orientation is often overlooked, and that Impella malrotation is a common issue in real-world clinical practice, potentially associated with relevant complications. 

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)